Sanofi Comments on Medivation’s Rejection of Proposal

Logo: Sanofi-Aventis
Logo: Sanofi-Aventis

Frankfurt am Main (pressrelations) –

Sanofi Comments on Medivation’s Rejection of Proposal

-Reiterates Commitment to Consummating Transaction-

Sanofi today commented on Medivation, Inc.’s (NASDAQ: MDVN) rejection of Sanofi’s non-binding all-cash proposal to acquire Medivation for $52.50 per share:

Combining Sanofi and Medivation represents a compelling strategic and financial opportunity to drive immediate and certain value for Medivation’s shareholders while benefiting patients and both companies’ respective stakeholders. Sanofi’s all-cash proposal represents over a 50 percent premium to Medivation’s two-month volume weighted average trading price (VWAP) prior to takeover rumors.

Sanofi is a disciplined acquirer and has a strong acquisition track-record. While to date Medivation has chosen not to enter into discussions regarding this value-creating transaction, Sanofi remains committed to the combination and looks forward to engaging directly with Medivation shareholders with regard to our proposal.

About Sanofi
Sanofi, a global healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients’ needs. Sanofi is organized into five global business units: Diabetes and Cardiovascular, General Medicines and Emerging Markets, Sanofi Genzyme, Sanofi Pasteur and Merial. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).

Pressekontakt:

Sanofi-Aventis Deutschland GmbH
Industriepark Höchst
65926 Frankfurt am Main

Telefon: 069/305-5085

Leave a reply:

Your email address will not be published.

Time limit is exhausted. Please reload CAPTCHA.

Site Footer